Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 33 for “"5-ASA"”.
-
Investigating the Use of 5-Aminosalicylic Acid for the Prevention of Sporadic Colorectal Carcinogenesis
… later developing CRC. 5-Aminosalicylic acid (5-ASA) is used extensively in ulcerative colitis and importantly reduces colitis associated cancer risk. 5-ASA is well-tolerated with an excellent safety profile making it a potential candidate for sporadic CRC prevention. However, the mechanisms …
-
Investigating the Effect of 5-aminosalicylic Acid on Colorectal Tumour Cell Metabolism
… adverse side effects. 5-aminosalicylic acid (5-ASA) is<br/>an ‘aspirin-like drug’ used clinically for the management of ulcerative colitis and <br/>importantly, is well-tolerated. 5-ASA is reported to reduce the risk of colitis-associated <br/>cancer and has shown promise for prevention of …
-
DEVELOPMENT OF AN ORAL MULTIPLE-UNIT DOSAGE FORM CONTAINING A HIGH LOAD OF 5-AMINOSALICYLIC ACID
… ACID Introduction 5-aminosalicylic acid (5-ASA) is the first-line drug therapy for mild to moderate acute exacerbations of IBD (Inflammatory Bowel Disease). 5-ASA is generally administered at the dosage regimen of 2.4 g/day, even though recent clinical trials have convincingly demonstrated …
-
Investigation into the production of calcium pectinate particles for oral delivery to the colon
… particles, loaded with 5 aminosalicylic acid (5-ASA) was explored. Their potential for controlled drug release to the colon was evaluated. Two production methods for the particles were explored; the ‘syringe droplet’ method and the ‘water in oil’ emulsion method. The characteristics of these …
-
Atomic Layer Deposition for Personalized Drug Release Systems: 5-Aminosalicylic Acid as a Model Pharmaceutical
… as a technique to coat 5-Aminosalicylic acid (5-ASA)—a drug to treat inflammatory bowel disease—to control 5-ASA's release throughout the gastrointestinal tract. 5-ASA was coated with 300 cycles of Al2O3 and 200 cycles ZnO ALD and was characterized by Fourier transform infrared spectroscopy …
-
Preparation, development and evaluation of novel drug delivery systems for colon targeting
… del colon: l’acido 5-amminosalicilico (5-ASA) e il metronidazolo (MTZ). Per la preparazione di questi sistemi sono stati scelti sistemi pH-dipendent ed enzima-dipendenti. Sistemi pH-dipendenti sono stati preparati con il 5-ASA. N-Succinyl-chitosano (SucCH) è stato usato come carrier …
-
ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΤΩΝ ΠΑΡΑΓΩΓΩΝ ΤΟΥ ΑΡΑΧΙΔΟΝΙΚΟΥ ΟΞΕΟΣ ΣΕ ΦΛΕΓΜΟΝΩΔΗ ΝΟΣΗΜΑΤΑ ΤΟΥ ΕΝΤΕΡΟΥ
… COLITIS, BEFORE AND AFTER TREATMENT WITH 5 - ASA 1,5 G ORALLY TAKEN EVERY DAY FOR 30 DAYS AND WERE COMPARED WITH RESULTS OF ELEVEN HEALTHY VOLUNTEERS. AFTER STATISTICAL ANALYSIS THE RESULTS CAN BE SUMMOND AS FOLLOWS: THE LEVEL OF PGE2 AND LTB4 IS HIGH IN THE TOTAL NUMBER OF PATIENTS AND …
-
Μελέτη της επίδρασης χημειοπροφυλακτικών παραγόντων στην απόπτωση κυττάρων του κολονικού επιθηλίου
… (COX)-2 inhibitors and 5-Amino-salicylate (5-ASA,) added alone or in combination with 5-fluorouracil (5-FU), on apoptosis and proliferation of 2 human colonic cancer cell lines (HT-29 and Caco-2) were the principal aims of the present study. Apoptosis was initially evaluated by …
-
The development of novel colon targeted drug delivery systems
… To deliver 5-aminosalicylic acid (5-ASA) into the colon without any drug loss in stomach, spherical 5-ASA loaded zein nanoparticles (NPs) were prepared by nanoprecipitation in order to incorporate them into the HPMCAS fibers. Single-step particle-in-fiber incorporation by co-axial …
-
Micropartículas poliméricas à base de xilana e Eudragit® S-100 contendo mesalazina visando à liberação cólon-específica
… molecule for the treatment of IBD, mesalazine (5-ASA) is rapidly absorbed in the upper gastrointestinal tract and its systemic absorption leads to risks of adverse effects. The aim of this work was to develop a microparticulate system based on xylan and Eudragit® S- 100 (ES100) for colon-specific …
-
Micropartículas de xilana contendo mesalazina visando a liberação no cólon
… mesalamine-loaded xylan microparticles (XMP5-ASA) by cross-linking polymerization using a non-hazardous cross-linking agent. The microparticles were characterized by thermal analysis (DSC/TG), X-ray diffraction (XRD), infrared spectroscopy (FTIR-ATR) and scanning electron microscopy (SEM). A …
-
Azathioprin bei chronisch entzündlichen Darmerkrankungen
… und Comedikation (Glukokortikosteroide und 5-ASA). Bei Patienten mit Morbus Crohn konnte in 31% der Fälle eine Remissionsinduktion mit Azathioprin erreicht werden. Die selbe Ansprechrate zeigte sich auch bei Patienten mit Colitis ulcerosa. Diese niedrige Ansprechrate ist wahrscheinlich auf die …
-
Mobile genetic elements in Campylobacter concisus and their clinical relevance in inflammatory bowel disease
… anti-inflammatory drug 5-aminosalicylic acid (5-ASA) on the growth of C. concisus and other enteric microbes were investigated. AZA and MP significantly inhibited the growth of all 11 C. concisus strains. Interestingly, 5-ASA showed inhibitory effect on some C. concisus strains, while it promoted …
-
Development of 3D printed controlled drug delivery systems by dual Fused Deposition Modelling (FDM): Role of formulation and internal geometry on modulation of drug release
… of the model drug 5-aminosalicylic acid (5-ASA) are introduced in Chapter I. Based on two model designs (Models 1 and 2), different formulations and geometries were chosen for each compartment. Regarding the formulation, hydroxypropyl methylcellulose acetate succinate (HPMCAS, HG and HMP …
-
Chemoprevention of colorectal cancer in inflammatory bowel diseases using routinely prescribed medications
… studies using the ResearchOne database, 5-ASA medications (OR 0.32, 95% CI 0.23 to 0.45), immunomodulators (OR 0.49, 95% CI 0.31 to 0.79), NA-NSAIDs (OR 0.68, 95% CI 0.49 to 0.95), non-aspirin antiplatelets (OR 0.41, 95% CI 0.20 to 0.84), and statins (OR 0.55, 95% CI 0.37 to 0.81) were …
-
Der frühe Morbus Crohn im Langzeitverlauf
… Ein Alter > 40 Jahre sowie eine Therapie mit 5-ASA bei Erstdiagnose (p < 0,012) zeigte eine Assoziation zu milden Verläufen. Zudem konnte gezeigt werden, dass das Verhalten (Behaviour) in der Montreal-Klassifikation im Langzeitverlauf relativ stabil bleibt und dass das penetrierende / …
-
Μικροβίωμα και ιδιοπαθή φλεγμονώδη νοσήματα εντέρου
… antibiotics. All of the adults received 5-ASA (± Azathioprine ± Cortisone) or Azathioprine. Using a sensitive reverse transcription–quantitative real-time PCR (RT-qPCR) method, we determined the composition of microbiota. NOD2/CARD15 genotyping, was also studied. Total bacterial DNA …
-
Retrospektive Analyse zum Vergleich des Einflusses einer frühen oder späten Intervention mit Tumornekrosefaktor-alpha-Antikörper-Therapie auf den Krankheitsverlauf bei Patienten mit Morbus Crohn
… und waren seltener mit Steroiden (p=0,014), 5-ASA (p< 0,001) oder Azathioprin (p< 0,001) vorbehandelt. Zwei Jahre nach TNF-AK-Erstgabe unterschied sich der CDAI in den beiden Gruppen nicht (89,4% vs. 87,9%, p = 0,737). Aber innerhalb von 2 Jahren erreichten FI-Patienten eine höhere …
-
Pharmakokinetik von Olsalazin beim Pferd
Pharmakokinetische Grundlagenuntersuchung nach oraler Applikation des Prodrugs Olsalazin im Hinblick auf dessen mögliche therapeutische Anwendung bei unspezifischen entzündlichen Dickdarmerkrankungen des Pferdes (z.B.Typhlokolitis).
-
Regulatory Elements of Polyphosphate Biosynthesis
… inhibitor mesalamine (5-aminosalicylic acid, 5-ASA), a poor inhibitor of polyH-tagged PPK, was found to be more effective when tested on the C-tagged enzyme. Finally, subtle differences in the previously described PPK* mutant enzymes were identified that suggest that each mutation leads to …
Page 1 of 2